

ANNUAL REPORT
FY 2024-2025

**INSTITUTE FOR STEM CELL SCIENCE AND
REGENERATIVE MEDICINE**



INDEPENDENT AUDITOR'S REPORT

To,
The Members
Governing Council of
M/s. Institute for Stem Cell Science and Regenerative Medicine
Bangalore-560065

Report on the Audit of the standalone Financial Statements

Opinion

We have audited the financial statements of "Institute for Stem Cell Science and Regenerative Medicine", which comprises the Balance Sheet as at 31st March 2025, the Income and Expenditure Account and Receipts and Payments account for the year then ended, and notes to the financial statements, including a summary of significant accounting policies.

In our opinion and to the best of our information and according to the explanations given to us, the accompanying financial statements give a true and fair view of the financial position of the Institute as at 31st March 2025, of its financial performance and Receipts and Payments for the year ended in accordance with the Accounting Standards issued by the Institute of Chartered Accountants of India (ICAI).

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) issued by ICAI. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the entity in accordance with the Code of Ethics issued by ICAI and we have fulfilled our other ethical responsibilities in accordance with the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.



Other Matters

We have not audited the financial statements of CSCR at Vellore, whose financial statements reflect total assets of Rs. 17.65 crores, total revenue of Rs.10.90 crores and excess of income over expenditure of Rs. 8.83 Lakhs for the year ended as on 31-03-2025. These financial statements have been audited by other auditor whose reports have been furnished to us by the Management.

Responsibilities of Management and Those Charged with Governance for the Financial Statements

Management is responsible for the preparation of the financial statements in accordance with generally accepted accounting principles in India. This responsibility includes the design, implementation and maintenance of internal control relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the entity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the entity or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the entity's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for



one resulting from error, as fraud may involve collusion forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the entity's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the entity to cease to continue as a going concern.


We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

For T. Ramachandran & Co.

Chartered Accountants

Firm Registration Number: 009009S


T. Ramachandran

Partner

Membership No.: 207600



Date: 22-09-2025

Place: Bangalore

UDIN: 25207600BMIAQS4782

GFR 12 - A (See Rule 238(1))
FORM OF UTILISATION CERTIFICATE FOR AUTONOMOUS BODIES OF THE GRANTEE ORGNISATION
 AUDITED UTILISATION FOR THE YEAR 2024-25 in respect of recurring/non recurring
 GRANTS-IN-AID/SALARIES/CREATION OF CAPITAL ASSETS

1. Name of the Scheme : Institute for Stem Cell Science and Regenerative Medicine
2. Whether recurring or no recurring grants
3. Grants position at the beginning of the Financial year
 (i) Cash in Hand/Bank
 (ii) Unadjusted advances
 (iii) Total

(3,08,29,579)
 -
 (3,08,29,579)

4. Details of grants received expenditure incurred and closing balances:(Actuals)

Unspent Balances of grants received years (Figure as at Sl. no 3(iii))	Interest earned thereon	Unspent Balance/ Interest deposited back to the Govt.	Grant received during the year			Total available Fund (1+2-3+4)	Expenditure incurred	Closing Balances (5-6)
1	2	3	4			5	6	7
			Sanction No. (i)	Date (ii)	Amount (iii)			
(3,08,29,579)	36,75,683	21,38,925	No. AID-19015/1/2020-MED-DBT	13.04.2024	5,60,00,000.00	68,59,22,905	67,19,58,788	1,39,64,117
			No. AID-19015/1/2020-MED-DBT	13.04.2024	11,60,00,000.00			
			No. AID-19015/1/2020-MED-DBT	13.04.2024	6,00,00,000.00			
			No. AID-19015/1/2020-MED-DBT	04.10.2024	4,80,00,000.00			
			No. AID-19015/1/2020-MED-DBT	04.10.2024	7,80,00,000.00			
			No. AID-19015/1/2020-MED-DBT	04.10.2024	4,00,00,000.00			
			No. AID-19015/1/2020-MED-DBT	24.10.2024	2,35,00,000.00			
			No. AID-19015/1/2020-MED-DBT	24.10.2024	6,85,00,000.00			
			No. AID-19015/1/2020-MED-DBT	24.10.2024	3,50,00,000.00			
			No. AID-19015/1/2020-MED-DBT		4,25,00,000.00			
			No. AID-19015/1/2020-MED-DBT		8,75,00,000.00			
			No. AID-19015/1/2020-MED-DBT		2,00,00,000.00			
			Other Receipts		4,02,15,726.00			
					71,52,15,726.00			

Component wise utilisation of grants

Grant in aid General	Grant in Aid - Salary	Grant in aid-creation of capital assets	Expenditure Against Other Receipts	Total
34,48,06,313	14,23,29,988	15,48,95,195	2,99,27,292	67,19,58,788

Details of Grant position at the end of the year

- (i) Cash in Hand/Bank 1,39,64,117
 (ii) Unadjusted advances
 (iii) Total 1,39,64,117

Certified that I have satisfied myself that the conditions on which grants were sanctioned have been duly fulfilled/are being fulfilled and that I have exercised following checks to see that the money has been actually utilized for the purpose for which it was sanctioned:

- (i) The main accounts and the other subsidiary accounts and registers (including assets registers) are maintained as prescribed in the relevant Act/Rules/Standing instructions (mentioned the Act/Rules) and have been duly audited by designated auditors. The figures depicted above tally with the audited figures mentioned in financial statements/accounts.
 (ii) There exist internal controls for safeguarding public funds/assets watching outcomes and achievements of physical targets against the financial inputs insuring quality in asset creation etc. & the periodic evaluation of internal controls is exercised to ensure their effectiveness.
 (iii) To the best of our knowledge and belief no transactions have been entered that are in violation of relevant Act/Rules/Standing instructions and scheme guidelines agreements (Tripartite Agreement) sanction letters contract agreements/LoAs/amendments in LoAs and agreements.
 (iv) The responsibilities among the key functionaries for execution of the scheme have been assigned in clear terms and are not general in nature.
 (v) The benefits were extended to the intended beneficiaries and only such areas/districts were covered where the scheme was intended to operate.
 (vi) The expenditure on various components of the scheme was in proportions authorized as per the scheme guidelines and terms and conditions of the grants-in-aid.


- (vii) It has been ensured that the physical and financial performance under IPDS has been according to the requirements as prescribed in the guidelines issued by Govt. of India and the
 (viii) The utilization of the fund resulted in outcomes given at Annexure-II duly enclosed (to be formulated by the Ministry/Department concerned as per their requirements/specifications).
 (ix) Details of various schemes executed by the agency through grants-in-aid received from the same Ministry or from other Ministries is enclosed at Annexure-II (to be formulated by the Ministry/Department concerned as per their requirements/specifications).


Note

1. Interest for FY 2023-24 - Rs. 21,36,132/- (inStem) & Rs.2793/- (CSCR) is refunded through Bharatkosh vide receipt No.0708240032082 dt.07.08.2024 and 1305240019863
2. Interest for FY 2024-25 - Rs. 36,73,423/- (inStem) & Rs.2260/- (CSCR) is refunded through Bharatkosh vide receipt No.1104250030186 dt. 11.04.2025, 1104250029662 dt. 11.04.2025 and 1809250016190 dt. 19.09.2025 Annexure-2


 (T Ramachandran)
 Partner (M.No.207600)
 Place: Bangalore
 Date : 22.09.2025


 मधु चंदन रॉय / Madhu Chandan Roy
 प्रशासनिक अधिकारी (वित्त एवं लेखा) / Administrative Officer (F&A)
 आइसीआर - मूल कोशिका विज्ञान एवं पुनर्योजी औषधि संस्थान (इन्स्टेम) /
 iBRIC - Institute for Stem Cell Science and Regenerative Medicine (inStem)
 जैव-प्रौद्योगिकी अनुसंधान और नवाचार परिषद, जैव प्रौद्योगिकी विभाग, विज्ञान एवं प्रौद्योगिकी मंत्रालय,
 भारत सरकार / Biotechnology Research and Innovation Council, Department
 of Bio-technology, Ministry of Science & Technology, Govt. of India
 जीकेवीके पोस्ट, बेल्लारी रोड, बेंगलूरु-560 065.
 GKVK POST, Bellary Road, Bangalore-560 065.


 (A. K. Prakash)
 Registrar


 (Prof. Maneesha Inamdar)
 Director

प्रो. मनीषा एस इनामदार / Prof. Maneesha S Inamdar
 निदेशक / Director
 स्टेम कोशिका विज्ञान एवं पुनर्योजी औषधि संस्थान (डीबीटी-इन्स्टेम)
 Institute for Stem Cell Science and Regenerative Medicine (DBT - inStem)
 जैव प्रौद्योगिकी विभाग, विज्ञान एवं प्रौद्योगिकी मंत्रालय,
 भारत सरकार के अधीन एक स्वायत्त संस्थान
 (An Autonomous Institute under Department of Biotechnology, MoST, Govt. of India)
 जीकेवीके पोस्ट, बेल्लारी रोड, बेंगलूरु-५६० ०६५.
 GKVK Post, Bellary Road, Bengaluru- 560 065.

DDIN: 252076003MIAQS4782

(A) under Department of Biotechnology, MoST, Govt. of India
 जीकेवीके पोस्ट, बेल्लारी रोड / GKVK Campus, Bellary Road
 बेंगलूरु-560 065 / Bengaluru - 560 065



INSTITUTE FOR STEM CELL SCIENCE & REGENERATIVE MEDICINE, BANGALORE
AUDITED STATEMENT OF EXPENDITURE FOR THE PERIOD FROM 01.04.2024 TO 31.03.2025

(Amount in Rs.)

Sl.No.	Particulars	Unspent balance as on 01.04.2024 as per Audited SOE & UC	Grants received from DBT for 01.04.2024 to 31.03.2025	Other receipts or interest earned	Total	Expenditure incurred (excluding commitments) from 01.04.2024 to 31.03.2025	Interest/Unspent amount Refunded/Lapsed	Balance as on 31.03.2025
1	2	3	4	5	6=3+4+5	7	8	9=6-7-8
	INSTEM :							
A	GIA - Capital	-1,04,805	12,16,00,000	-	12,14,95,195	12,14,95,195	-	-
B	GIA - Salary	-2,76,70,012	15,72,36,683	-	12,95,66,671	12,95,66,671	-	-
C	GIA - General	-51,93,687	25,37,43,317	-	24,85,49,630	24,85,49,630	-	-
D	Other receipts	-	-	4,02,15,726	4,02,15,726	2,99,27,292	-	1,02,88,434
E	Interest Earned/Refunded	21,36,132	-	36,73,423	58,09,555	-	21,36,132	36,73,423
	TOTAL (A+B+C+D+E+F) - INSTEM	-3,08,32,372	53,25,80,000	4,38,89,149	54,56,36,777	52,95,38,788	21,36,132	1,39,61,857
	CSIR Vellore :							
G	GIA - Capital	-	3,34,00,000	-	3,34,00,000	3,34,00,000	-	-
H	GIA - Salary	-	1,27,63,317	-	1,27,63,317	1,27,63,317	-	-
I	GIA - General	-	9,62,56,683	-	9,62,56,683	9,62,56,683	-	-
J	Other receipts	-	-	-	-	-	-	-
K	Interest Earned	2,793	-	2,260	5,053	-	2,793	2,260
	TOTAL (G+H+I+J+K+L) - CSIR	2,793	14,24,20,000	2,260	14,24,25,053	14,24,20,000	2,793	2,260
	CONSOLIDATED							
M	GIA - Capital	-1,04,805	15,50,00,000	-	15,48,95,195	15,48,95,195	-	-
N	GIA - Salary	-2,76,70,012	17,00,00,000	-	14,23,29,988	14,23,29,988	-	-
O	GIA - General	-51,93,687	35,00,00,000	-	34,48,06,313	34,48,06,313	-	-
P	Other receipts	-	-	4,02,15,726	4,02,15,726	2,99,27,292	-	1,02,88,434
Q	Interest Earned	21,38,925	-	36,75,683	58,14,608	-	21,38,925	36,75,683
	GRAND TOTAL (M+N+O+P+Q+R)	-3,08,29,579	67,50,00,000	4,38,91,409	68,80,61,830	67,19,58,788	21,38,925	1,39,64,117

1. Interest for FY 2023-24 - Rs. 21,36,132/- (inStem) & Rs. 2793 (CSIR) is refunded through Bharatkosh vide receipt No.0708240032082 dt.07.08.2024 and 1305240019863 dt.13.05.2024 Annexure-1.
2. Interest for FY 2024-25 - Rs. 36,73,423/- (inStem) & Rs.2260 (CSIR) is refunded through Bharatkosh vide receipt No.1104250030186 dt. 11.04.2025, 1104250029662 dt. 11.04.2025 and 1809250016190 dt.19.09.2025 Annexure-2

(T Ramachandran)
Partner (M.No.207600)
Place: Bangalore
Date : 22.09.2025

(Madhu Chandan Roy)
Admin Officer (F&A)
Unit, Department of Bio-technology, Ministry of Science & Technology, Govt. of India
जी.के.पी. रोड, बेल्लारी रोड, बंगलूर - 560 065 /

(AK Prakash)
Registrar
मूल कोशिका विज्ञान एवं पुनर्वाजी औषधि संस्थान (डीबीटी-इंस्टेम)
Institute for Stem Cell Science and Regenerative Medicine (DBT - inStem)
जीव प्रौद्योगिकी विभाग, विज्ञान एवं प्रौद्योगिकी मंत्रालय, भारत सरकार के अधीन एक स्वायत्त संस्थान

(Prof. Maneesha S Inamdar)
स्टेम कोशिका विज्ञान एवं पुनर्वाजी औषधि संस्थान (डीबीटी-इंस्टेम)
Institute for Stem Cell Science and Regenerative Medicine (DBT - inStem)
जीव प्रौद्योगिकी विभाग, विज्ञान एवं प्रौद्योगिकी मंत्रालय, भारत सरकार के अधीन एक स्वायत्त संस्थान
(An Autonomous Institute under Department of Biotechnology, MoST, Govt of India)

INCOME AND EXPENDITURE ACCOUNT FOR THE YEAR ENDED MARCH 31, 2025

Particulars	Schedule	CY 2024-25	PY 2023-24
INCOME			
Income from Projects - to the extent of expenditure included	3	24,71,70,719	17,27,23,704
Income from Sales and Services	12	2,15,84,776	2,60,52,807
Grants/Subsidies	13	52,00,00,000	51,23,00,000
Fees/Subscriptions	14	-	-
Income from Investments	15	-	-
Income from Royalty, Publications etc.	16	-	-
Interest earned	17	40,88,429	23,85,642
Other Income	18	1,86,32,752	80,42,125
Increase/(decrease) in stock of finished goods and works-in-progress	19	-	-
TOTAL (A)		81,14,76,676	72,15,04,278
EXPENDITURE			
Establishment Expenses	20	14,22,25,924	12,40,91,845
Other Administrative Expenses	21	37,04,62,659	34,98,80,140
Expenditure on Grants/Subsidies etc.	22	24,71,70,719	17,27,23,704
Interest	23	36,75,683	5,81,934
Depreciation (Net Total at the year-end -corresponding to Sch.8)		26,96,99,112	28,73,43,683
TOTAL (B)		1,03,32,34,097	93,46,21,306
Balance being excess of Expenditure over Income (A-B)		-22,17,57,421	-21,31,17,028
Less- Transfer from Capital Reserve - equivalent to depreciation charges	2(1)	26,96,99,112	28,73,43,683
Less- Transfer to/from General Reserve - Recurring Grant Account	1(B)	4,79,41,691	7,42,26,655
Balance being surplus/deficit carried to Corpus/Capital Fund		-	-

INSTITUTE FOR STEM CELL SCIENCE AND REGENERATIVE MEDICINE BANGALORE

(Registered under the Karnataka Societies' Registration Act.)

GKVK, BELLARY ROAD, BANGALORE - 560 065

BALANCE SHEET AS AT MARCH 31, 2025

Particulars	Schedule	CY 2024-25	PY 2023-24
CORPUS/CAPITAL FUND AND LIABILITIES			
CORPUS/CAPITAL FUND	1	17,56,01,925	12,83,53,021
RESERVES AND SURPLUS	2	2,17,98,65,863	2,22,57,01,940
EARMARKED/ ENDOWMENT FUNDS	3	21,44,45,066	24,89,32,285
SECURED LOANS AND BORROWINGS	4	-	-
UNSECURED LOANS AND BORROWINGS	5	-	-
DEFERRED CREDIT LIABILITIES	6	-	-
CURRENT LIABILITIES AND PROVISIONS	7	4,20,31,491	5,31,39,895
TOTAL		2,61,19,44,344	2,65,61,27,141
ASSETS			
FIXED ASSETS	8	2,22,69,89,778	2,27,28,25,856
INVESTMENTS - FROM EARMARKED /ENDOWMENT FUNDS	9	-	-
INVESTMENTS - OTHERS	10	600	600
CURRENT ASSETS, LOANS, ADVANCES ETC.	11	38,49,53,966	38,33,00,685
TOTAL		2,61,19,44,344	2,65,61,27,141
SIGNIFICANT ACCOUNTING POLICIES	24		
CONTINGENT LIABILITIES AND NOTES ON ACCOUNTS	25		

Vide our report of even date
For T Ramachandran & Co
Chartered Accountants



(T Ramachandran)
Partner (M.No.207600)

Place: Bangalore
Date : 22.09.2025

UDIN: 25207600BMTIARS4782

मधु चंदन राय / Madhu Chandan Roy
प्रशासनिक अधिकारी (F&A)
(Madhu Chandan Roy) Administrative Officer (F&A)
आर्थिक - प्रशासनिक अधिकारी (इन्स्टीट्यूट)
iBRC - Institute for Stem Cell Science and Regenerative Medicine (inStem)
इस प्रयोगशाला में अनुसंधान और विकास परियोजनाएं, विकास और प्रौद्योगिकी मंत्रालय,
भारत सरकार / Biotechnology Research and Innovation Council, Department
of Bio-technology, Ministry of Science & Technology, Govt. of India
केंद्र, बेल्लारी रोड, बेल्लारी - 560 065
पिन कोड: 560 065
पिन कोड: 560 065
(AI under Department of Biotechnology, MoST, Govt. of India)
बैंगलूरु-560 065 / Bengaluru - 560 065.

(AK Prakash)
Registrar

ए.के. प्रकाश / A K Prakash
रजिस्ट्रार / Registrar

(Prof. Maneesha Inamdar)
Director

प्रो. मनीषा एस इनमदार / Prof. Maneesha S Inamdar
निदेशक / Director


स्टेम कोशिका विज्ञान एवं पुनर्योजी औषधी संस्थान (डीबीटी-इंस्टीट्यूट)
Institute for Stem Cell Science and Regenerative Medicine (DBT - inStem)
जैव प्रौद्योगिकी विभाग, विज्ञान एवं प्रौद्योगिकी मंत्रालय,
भारत सरकार के अधीन एक स्वायत्त संस्थान
An Autonomous Institute under Department of Biotechnology, MoST, Govt. of India
बैंगलूरु-560 065
बैंगलूरु-560 065.

GKVK Post, Bellary Road, Bengaluru- 560 065.

INSTITUTE FOR STEM CELL SCIENCE & REGENERATIVE MEDICINE, BANGALORE
(Registered under the Karnataka Societies' Registration Act)
GKVK, BELLARY ROAD, BANGALORE - 560 065
RECEIPTS AND PAYMENTS STATEMENT FOR THE YEAR ENDED MARCH 31, 2025

				(Amount - Rs)
RECEIPTS	CY 2024-25	PY 2023-24	PAYMENTS	
I. Opening Balances			I. Expenses	PY 2023-24
a) Cash in hand	-	24	a) Establishment Expenses	14,22,25,924
b) Bank Balances			b) Administrative Expenses	37,25,84,124
i) in current accounts	3,61,49,246	90,21,512		51,48,10,048
ii) in deposit accounts	20,28,71,004	3,05,97,889	II. Payments made against projects	17,27,23,704
iii) in savings accounts	7,14,80,461	12,04,67,505	III. Investments made	
	31,05,00,711	16,00,86,930	a) Out of Earmarked/End. Funds	-
II. Grants Received			b) Out of own funds	-
a) From Govt. of India	67,50,00,000	66,23,00,000	IV. Increase in Current Assets	3,67,04,255
b) From State Govt.	-	-	V. Capital Expenditure	
	67,50,00,000	66,23,00,000	a) Purchase of fixed assets-Projects	6,87,54,952
III. Project Receipts-Projects	32,80,16,625	37,00,72,374	b) Exp. On Building	1,29,20,521
			c) Exp on Equipments & Furnitures	9,97,59,179
IV. Decrease in Current Assets	10,21,749	-		14,70,61,532
V. Interest Received			VI. Refund of surplus money/Loans	
a) On Bank deposits	2,08,96,366	1,07,34,006	a) To the Govt. of India	10,37,126
b) on Loans, Advances etc.	-	-	a) To the Govt. of India-EMG	7,06,16,470
	2,08,96,366	1,07,34,006		7,16,53,596
VI. Other Income (Specify)	4,02,17,528	3,40,94,932	VII. Finance Charges (Interest)	
VII. Amount Borrowed	-	-	VIII. Decrease in Current Liabilities	2,11,74,930
VIII. Any other receipts	-	-	IX. Closing Balances:	
IX. Increase in Current Liabilities	-	-	a) Cash in hand	-
			b) Bank Balances	3,61,49,246
			i) in current accounts	20,28,71,004
			ii) in deposit accounts	7,14,80,461
			iii) in savings accounts	31,31,75,741
TOTAL	1,37,56,52,979	1,23,72,88,242	TOTAL	1,37,56,52,979

Vide our report of even date
For T Ramachandran & Co
Chartered Accountants



(T Ramachandran)
Partner (M.No.207600)

Place: Bangalore
Date : 22.09.2025

(Prof. Maneesha Inamdar)
 प्रो. मनीषा एस इनामदार / Director
 निदेशक / Director
 स्टेम कोशिका विज्ञान एवं पुनरावर्जी औषधी संस्थान (डीबीटी-इंस्टीट्यूट)
 Institute for Stem Cell Science and Regenerative Medicine (DBT - inStem)
 जैव प्रौद्योगिकी विभाग, विज्ञान एवं प्रौद्योगिकी मंत्रालय,
 भारत सरकार के अधीन एक स्वायत्त संस्थान
 Autonomous Institute under Department of Biotechnology, MoST, Govt. of India
 जीकेवीके पोस्ट, बेल्लारी रोड, बेंगलूरु-५६० ०६५.
 GKVK Post, Bellary Road, Bengaluru - 560 065.

UDIN: 25207600B/MIA/254782

INSTITUTE FOR STEM CELL SCIENCE AND REGENERATIVE MEDICINE BANGALORE
(Registered under the Karnataka Societies' Registration Act.)
GKVK, BELLARY ROAD, BANGALORE - 560 065
SCHEDULES FORMING PART OF FINANCIAL STATEMENTS AS AT MARCH 31, 2025

(Amount- Rs.)

SCHEDULE-1 - CORPUS/CAPITAL FUND:	CY 2024-25	PY 2023-24
(A) NON-RECURRING GRANT		
Balance at the beginning of the year	8,30,95,103	4,57,74,803
Add: Contributions during the year	15,50,00,000	15,00,00,000
Less: Expenditure incurred during the year	15,51,08,081	11,26,79,700
Adjustments, if any *	-	-
BALANCE AS AT THE YEAR END (A)	8,29,87,022	8,30,95,103
(B) RECURRING GRANT		
Balance as at the beginning of the year	4,52,57,918	-2,50,16,015
Grants returned to DBT	-	-4,55,192
Adjustment pertaining to previous years *	-5,84,707	-34,97,530
Transferred from Income & Expenditure	4,79,41,691	7,42,26,655
BALANCE AS AT THE YEAR END (B)	9,26,14,902	4,52,57,918
TOTAL (A) + (B)	17,56,01,925	12,83,53,021

Note: Adjustments made in recurring Grant includes (Rs.21,38,925 + Rs. 1,01,665 - Rs.1655883 = Rs. 5,84,707)

1. Interest refunded to DBT for FY 2023-24 amounting to Rs.21,38,925/- .
2. Amount received pertaining to Previous Financial Years amounting to Rs. 16,55,883/-
3. Amount receivable from DBT against workshop amounting to Rs.1,01,665/-


(Amount- Rs.)

SCHEDULE -2 - RESERVES AND SURPLUS:	CY 2024-25	PY 2023-24
1: CAPITAL RESERVE		
As per last account	2,22,57,01,941	2,36,59,84,315
Add: Adjustments of previous years	-	-223
Addition during the year - Capital addition	22,38,63,034	14,70,61,532
Less: Deduction during the year - Depreciation	26,96,99,112	28,73,43,683
TOTAL	2,17,98,65,863	2,22,57,01,940
2: REVALUATION RESERVE:	-	-
3: SPECIAL RESERVES:	-	-
4: GENERAL RESERVE:	-	-
Total Reserves & Surplus	2,17,98,65,863	2,22,57,01,940



SCHEDULE -3-EARMARKED / ENDOWMENT FUNDS

Sl No.	Project Title (Name of PI if applicable)	Budget code	Funding Agency	Opening Balance	Received during the year	Refund during the year	Interest received	Interest Refunded	Expenditure		Adjustment	Total Expenditure	Balance as on 31-03-2025
									Capital	Revenue			
A	From Government												
1	DBT JRF (8138-Ondrila Banerjee)	8138	DBT	15,862	-	-	-	-	-	-	-	-	15,862
2	Mahendra Rao (8146)	8146	-	18,74,804	-	-	-	-	-	-	-	-	18,74,804
3	DBT JRF Fellowship (8149-Bhakti J Vyasa)	8149	DBT	1,02,000	-	-	-	-	-	-	-	-	1,02,000
4	DBT JRF Fellowship (8163-Mohd M)	8163	DBT	1,04,028	-	-	-	-	-	-	-	-	1,04,028
5	ICMR Fellowship (8155-Radhika Rao)	8155	ICMR	27,208	-	-	-	-	-	-	-	-	27,208
6	ICMR Fellowship (8158-Edries Y H)	8158	ICMR	2,07,265	-	-	-	-	-	-	-	-	2,07,265
7	ICMR Fellowship (8159-Isha Rana)	8159	ICMR	-22,400	-	-	-	-	-	-	-	-	-22,400
8	CSIR Fellowship (8162-Abhinava Yadav)	8162	CSIR	15,068	-	-	-	-	-	-	-	-	15,068
9	CSIR Fellowship (8164-Lakshmi Kripa)	8164	CSIR	20,000	-	-	-	-	-	-	-	-	20,000
10	CSIR Fellowship (8166-Intiyaz Gulami)	8166	CSIR	34,998	-	-	-	-	-	-	-	-	34,998
11	DBT RA Fellowship (8167-Anupam Duttal)	8167	DBT	13,048	-	-	-	-	-	-	-	-	13,048
12	DBT RA Fellowship (8168-Anuree Mahanta)	8168	DBT	66,567	-	-	-	-	-	-	-	-	66,567
13	DBT JRF Fellowship (8173-Harshadri)	8173	DBT	9,166	-	-	-	-	-	-	-	-	9,166
14	DBT JRF Fellowship (8179-Sonal Joshi)	8179	DBT	20,000	-	-	-	-	-	-	-	-	20,000
15	DBT JRF Fellowship (8180-Vishwaja Javeri)	8180	DBT	1,68,760	-	-	-	-	-	-	-	-	1,68,760
16	DST Inspire Fellowship (8181-Manisha Goyal)	8181	DST - INSPIRE	-2,693	3,37,653	1,64,913	-	-	-	2,16,140	-	2,16,140	46,093
17	DST SRF Fellowship (8182-Pratul Jain)	8182	DBT	42,520	1,30,200	-	-	-	-	1,30,200	-	1,30,200	42,520
18	DST Inspire Fellowship (8184-Michelle Dsouza)	8184	DST - INSPIRE	-2,15,230	3,14,442	85,384	-	-	-	-	-	-	13,828
19	DST Inspire Fellowship (8185-Sreesa Sreedharan)	8185	DST - INSPIRE	-2,693	8,23,339	2,09,189	-	-	-	6,70,054	-	6,70,054	58,597
20	DBT RA Fellowship (8188-Gaurav Singh)	8188	DBT	2,94,980	10,71,080	-	-	-	-	12,94,670	-	12,94,670	71,390
21	ICMR Fellowship (8189-Pratul Jain)	8189	ICMR	3,262	1,64,148	-	-	-	-	1,09,548	-	1,09,548	57,862
22	ICMR Fellowship (8190-Vinay J Rao)	8190	ICMR	23,175	1,16,183	-	-	-	-	1,36,183	-	1,36,183	3,175
23	DBT JRF Fellowship (8191-Radhika Agrawal)	8191	DBT	22,723	8,59,279	-	-	-	-	8,82,002	-	8,82,002	53,520
24	DBT JRF Fellowship (8192-Ravi Kiran)	8192	DBT	1,11,600	-	-	-	-	-	58,080	-	58,080	1,176
25	CSIR Contingency received to Sreenath R. (8127)	8127	CSIR	1,176	-	-	-	-	-	-	-	-	39,758
26	Sumana Ghosh (8186)	8186	CSIR	39,758	-	-	-	-	-	-	-	-	1,34,409
27	DBT JRF Fellowship (8194-Aashwin Venkateshwarar)	8194	DBT	1,69,019	5,93,880	-	-	-	-	6,28,490	-	6,28,490	2,08,320
28	DBT JRF Fellowship (8195-Sneha Muraidharan)	8195	DBT	2,08,320	-	-	-	-	-	-	-	-	2,75,209
29	DBT JRF Fellowship (8196-Diksha Gogia)	8196	DBT	1,61,049	5,93,880	96,195	-	-	-	4,79,720	-	4,79,720	49,683
30	DST Inspire Fellowship (8197-Saraswati Sanjay Chavda)	8197	DST - INSPIRE	-2,693	1,25,195	-	-	-	-	75,990	-	75,990	10,30,694
31	DBT JRF Fellowship (8198-Sahana Vasudevan)	8198	DBT	-1,05,579	20,50,720	-	-	-	-	8,94,447	-	8,94,447	3,11,076
32	DBT JRF Fellowship (8200-Susobhan Mahanty)	8200	DBT	-66,560	11,43,320	-	-	-	-	7,65,684	-	7,65,684	66,129
33	DBT JRF Fellowship (8201-Sanjana Mullick)	8201	DBT	4,98,129	4,74,000	-	-	-	-	9,06,000	-	9,06,000	97,282
34	DBT JRF Fellowship (8202-Jagriti Arora)	8202	DBT	16,333	5,93,880	-	-	-	-	5,12,931	-	5,12,931	50,000
35	DBT JRF Fellowship (8203-Suchieta Dey)	8203	DBT	3,16,000	4,74,000	-	-	-	-	7,40,000	-	7,40,000	37,500
36	DBT JRF Fellowship (8204-Prasanna Venkata Lakshmi Devarakonda)	8204	DBT	-	5,92,500	-	-	-	-	5,55,000	-	5,55,000	50,000
37	DBT JRF Fellowship (8205-Nikhil Kumar Jalagam)	8205	DBT	-	7,90,000	-	-	-	0	7,40,000	-	7,40,000	3,31,408
38	DST Inspire Fellowship (8206-Anhavi Samarjit Sethe)	8206	DST - INSPIRE	-	6,26,322	5,12,830	-	-	-	4,44,300	-	4,44,300	20,000
39	DBT JRF Fellowship (8207-Aman Gangwar)	8207	DBT	-	3,16,000	-	-	-	-	2,96,000	-	2,96,000	20,000
40	DBT JRF Fellowship (8208-Nehal)	8208	DBT	-	3,16,000	-	-	-	-	2,96,000	-	2,96,000	3,70,118
41	Novel Cell Surface Markers for endodermal stem and progenitor cells in health and disease (8214) & CSIR	8214	DBT	3,70,118	-	-	-	-	-	-	-	-	7,54,889
42	Therapeutic approaches to augmentation of Adult cardiac stem cells (8217- Prof. Jyotsna Dhawan)	8217	DBT	7,54,889	-	-	-	-	-	-	-	-	3,88,853
43	DBT Twinning Programme for the North East - Molecular Mechanism of target recognition and cleavage by the CRISPR-Cas bacterial immune system (8220-Prof. Ramaswamy)	8220	DBT	3,88,853	-	-	-	-	-	-	-	-	1,15,628
44	Actomyosin-Dependent Transfer of RNA from Gliato Axons Muscle SC self renewal: A stressful matter (8225- CEHPRA Grant - Prof. Jyotsna Dhawan)	8225	CEHPRA	1,87,054	-	-	-	-	-	-	-	-	1,87,054
45	Regulation of epithelial stem cell homing in cutaneous wound healing (8226- Dr. Subhasit Ghosh)	8226	WT/DBT IA	-1,59,784	-	-	-	-	-	-	-	-	-1,59,784



Sl No.	Project Title (Name of PI if applicable)	Budget code	Funding Agency	Opening Balance	Received during the year	Refund during the year	Interest received	Interest Refunded	Expenditure	Advance	Adjustment	Total Expenditure	Balance as on 31-03-2025
47	"Deciphering molecular mechanisms of hydra regeneration through comparative transcriptome and small noncoding RNA profiling"	8228	DBT	-	2,05,448	-	-	-	-	-	-	-	2,05,448
48	Molecular mechanisms that regulate cyto skeletal modelling in cardiac hypertrophy by developing an in-vitro human cardiomyocyte culture microfluidic system (8229 - Prof. Jyotsna Dhiwan)	8229	DST	4,51,756	-	-	-	-	-	-	-	-	4,51,756
49	Imaging synaptic plasticity an control: Novel protein carbon nanotube fluorescent sensors for regulation of protein translation- (8239 Dr. Akash Guliyani)	8239	DBT	5,36,842	-	-	-	-	-	-	-	-	5,36,842
50	Structure-Function studies on nucleotide sugar transporters Indo Argentina program (8249-Prof Ramaswamy)	8249	DST	-43,335	-	-	-	-	-	-	-	-	-43,335
51	Accelerating the application of stem cell technology in human disease (ASHD)-8251 (Prof. Apurva, Dr. Raghu Padinjal)	8251	DBT ZBSA	-12,19,170	1,35,42,668	1,34,98,217	-	-	-	-	-	-	-11,74,719
52	Mining the Genome and Metagenome of Marine Microbiome for PKS-NRPS Biosynthetic Gene Cluster and Bioactive Small Molecules : A Coordinated R & D Initiative in marine Genomics (8257-Dr. Praveen Kumar Vemula)	8257	DBT	1,74,294	-	-	-	-	-	-	-	-	1,74,294
53	Ramalinga Swamy Grant (8258- Tina Mukharjee)	8258	DBT	2,50,309	-	-	-	-	-	-	-	-	2,50,309
54	NeuroStem : Stem cell Models for Discovery of RNA Mediated regulation in Neurodegeneration (8260- Dr. Ravi Muddipati)	8260	DBT	-3,96,121	-	-	-	-	-	-	-	-	-3,96,121
55	Genetic Program Controlling Mesoderm Differentiation (8272- Ram Kumar Sambasivan)	8272	DBT	1,84,669	-	-	-	-	7,050	-	-	7,050	1,77,619
56	Implementation of Phase-II for Centre for Chemical Biology and Therapeutics (CCBT) (8274-Prof. Ashok Venkataraman)	8274	DBT ZBSA	-24,01,339	91,51,826	91,51,826	-	-	-	-	-	-	-24,01,339
57	Financial approval of the Swarna Jayanti Fellowship to Dr. Dasaradhi Palakodeti (8276 Dasaradhi Palakodeti)	8276	DST	-36,878	-	-	-	-	-	-	-	-	-36,878
58	Role of Mechanical Signaling in Maintaining Stem Cell Quiescence in Mouse Skin (8277- Srikala Raghavan)	8277	SERB	-8,07,594	-	-	-	-	-	-	-	-	-8,07,594
59	Metabolic Regulation of Fungal Morphogenesis (8286- Dr. Sriram V)	8286	WT/DBT IA	31,217	-	-	-	-	-	-	-	-	31,217
60	Structure-Function Studies on Nucleotide Sugar Transporters (8291- S Ramaswamy)	8291	SERB	-6,69,094	-	-	-	-	-	-	-	-	-6,69,094
61	N PDF Fellowship to Dr. Venkataraman G. Rao (8454)	8454	SERB	-5,20,166	-	-	-	-	-	-	-	-	-5,20,166
62	Elucidating the function of the euchromatic histone lysine methyltransferase 1 (EHMT 1) in obesity and diabetes (8455 Mahua Chakraborty)	8455	DST	-8,99,103	-	-	-	-	-	-	-	-	-8,99,103
63	Regulation of damage-induced cellular plasticity in the lung (8456 Arjun Guha)	8456	CEPRRA	-5,49,746	-	-	-	-	-	-	-	-	-5,49,746
64	Characterization of novel variant human embryonic stem cells with features of neoplastic progression 8460 Shrivanti Rampalli	8460	SERB	12,383	-	-	-	-	-	-	-	-	12,383
65	Dissecting the Role of chromatin remodeling factor TIP60 in regulation of regeneration in Planaria (8461 Bharti Isswal)	8461	DST	-1,08,798	-	-	-	-	-	-	-	-	-1,08,798
66	Molecular, structural and functional mapping of eye regeneration using novel light sensing assays (8463 Akash Guliyani)	8463	SERB	-2,27,284	-	-	-	-	-	-	-	-	-2,27,284
67	Fabrication of Catalytic nano-Fibre based facemask and clothing to prevent pesticide-induced neuronal dysfunction and mortality (8468- Prof. Praveen Kumar Vemula)	8468	DBT ZBSA	-3,009	-	3,009	-	-	-	-	-	-	-
68	Profiling of bromodomain specific interacting partners using unnatural amino acid mutagenesis (Ramalingaswami Fellowship)- (8473-Dr. Sonia Sen)	8473	DBT	3,88,742	-	-	6,680	-	-	1,94,284	-	1,94,284	2,01,138
69	Regulation of cerebral cortical development by chromatin modifiers in health and disease (8475- Dr. Bhavana Muralidharan)	8475	WT/DBT IA	1,46,065	1,25,56,328	-	-	-	88,838	87,75,441	-	1,14,64,960	12,86,031
70	Leveraging stem cell technology to facilitate discovery for human disease biology in India (8479- Prof. Apurva Sarin/ Prof. Raghu Padinjal)	8479	DBT ZBSA	-21,91,315	46,64,720	-	1,37,435	-	-	6,00,438	-	6,00,438	-24,28,144
71	Regulation of metabolic homeostasis by Trna modifications (8483- Dr. Sunil Laxman)	8483	SERB	-17,295	-	-	-	-	-	-	-	-	-17,295
72	Delineating the Immune Epithelial Crosstalk in Embryonic Skin (8484- Dr. Srikala Raghavan/ Dr. Dasaradhi Palakodeti)	8484	DBT ZBSA	-11,01,705	13,13,196	10,32,892	-	-	-	3,71,914	-	3,71,914	-11,93,315
73	Architecture of axonemal doublet microtubule inner junction (8485- Dr. Minhal Sirajuddin)	8485	SERB	-2,54,918	25,4918	0	-	-	-	-	-	-	-
74	Early Career Fellowship to Dr. Anusree Mahanta (8486)	8486	WT/DBT IA	10,76,746	22,08,779	-	-	16,346	-	16,97,234	-	16,97,234	15,71,945
75	High-affinity binders against Covid 19 spike protein using display libraries (8492)	8492	DBT	-7,87,372	7,87,372	-	-	-	-	-	-	-	-
76	COVID-19 Bioresource (8493)	8493	DBT ZBSA	-1,38,294	1,38,294	-	-	-	-	-	-	-	-

Sl No.	Project Title (Name of PI if applicable)	Budget code	Funding Agency	Opening Balance	Received during the year	Refund during the year	Interest received	Interest Refunded	Expenditure	Advance	Adjustment	Total Expenditure	Balance as on 31-03-2025
78	Single Cell metabolic maps of senescent cells and senescence driven cancer cells in aging (8495)	8495	SERB	-9,54,698	-	-	-	-	-	-	-	-	-9,54,698
79	Epigenetic Regulation of the Wound Healing Program (8498)	8498	DBT ZBSA	-40,29,637	39,31,282	39,31,282	-	-	-	-	-	-	-40,09,285
80	Characterize the role of Angiogenin and Trna derived small RNAs in early embryogenesis (8502)	8502	DBT ZBSA	-13,60,166	35,24,771	20,07,593	-	-	19,43,581	-	-	19,43,581	-17,86,569
81	Deciphering the molecular mechanisms of dysregulation caused by mutations in LSD1 leading to Intellectual Disability (19A-2022)	8605	DBT ZBSA	-8,21,616	25,42,416	21,01,529	-	-	8,96,247	-	-	8,96,247	-12,76,976
82	Pre-Clinical evaluation of promising drugs for a rare syndromic cardiomyopathy in children	8606	BIRAC	-11,90,900	13,69,130	-	-	-	1,78,230	-	-	1,78,230	-
83	Translational platforms for discovery, repurposing and clinical development for Covid-19 therapeutics	8607 & 8608	DBT ZBSA	-41,46,074	1,19,27,441	22,48,772	-	-	65,15,932	-	-	77,19,456	-21,86,861
84	Immune Cell lipid homeostasis by the Notch pathway functions as a central regulator of animal growth control both in homeostasis and conditions of dietary Stress	8609	SERB	-72,910	-	-	-	-	-	-	-	-	-72,910
85	NPDF to Dr. Abir Rizvi	8610	SERB	1,85,247	1,18,057	-	-	-	3,03,304	-	-	3,03,304	-
86	Novel micropatterned cardiac organoid model for deciphering the pathophysiology of cardiomyopathy	8611	DBT ZBSA	-2,45,839	34,76,177	13,82,764	-	-	26,38,684	-	-	26,38,684	-7,91,110
87	Faculty Travel Award to Dr. Tina Mukherjee	8613	SERB	101	-	-	-	-	101	-	-	101	-
88	Elucidating the Structural and Functional Characterization of Membrane and Envelope Protein from SARS CO V-2 and its variants in Virus like Particle formation and its role in the virus assembly and release	8616	ICMR	2,73,958	12,49,066	-	-	-	10,30,872	-	-	10,30,872	4,92,152
89	The role of Galectin-3/LGALS3 in mediating epithelial defences against urinary tract infection by constitutive activation of the NF-κB pathway	8617	SERB	5,45,053	3,50,000	56,365	7,638	7,638	-	-	-	8,38,688	-
90	Enabling Covid-19 vaccine and therapeutics development using animal models	8618	BIRAC	2,32,26,857	-	1,13,39,132	-	-	1,18,82,188	-	-	1,18,82,188	5,537
91	Developing CRISPR-Cas9 based genome engineering technology for homology independent genetic manipulation at endogenous genomic loci in a tissue specific manner	8619	DBT ZBSA	-1,18,436	12,12,831	-	-	-	11,73,304	51,250	-	12,24,554	1,30,259
92	Understanding and manipulating how resource allocations drive collective cell functions	8623	WT/DBT IA	1,16,30,689	-	-	1,67,144	-	2,78,480	96,32,759	-	99,11,239	18,86,594
93	Role of tubulin posttranslational modifications in regulating primary cilium functions in wound healing and tissue homeostasis	8625	WT/DBT IA	26,62,513	39,53,363	-	79,064	2,63,847	-	62,06,189	-	62,06,189	2,24,904
94	Regulation of immune defenses and homeostasis at the urethral barrier	8626	WT/DBT IA	4,54,536	29,59,895	-	41,444	65,464	58,184	33,32,179	-	33,90,363	49
95	Immune cells as mobile sensors of animal physiology	8627	WT/DBT IA	57,58,367	1,06,83,006	-	2,89,087	1,20,560	21,86,666	74,85,971	-	96,72,637	69,37,263
96	Development of machine for rapid fabrication of the biocompatible micro needles, followed by clinical testing u	8628	SERB	64,528	-	-	968	-	-	1,04,936	-	1,04,936	-39,440
97	NPDF Fellowship of Shabir Ahmad	8629	SERB	-93,935	17,19,400	-	-	-	-	15,52,081	-	16,28,355	-2,890
98	Functional genomics of congenital heart disease	8631	DBT ZBSA	-6,78,088	10,67,798	3,74,847	-	-	-	11,00,253	-	11,00,253	-10,85,390
99	IRMI Research Management Grant	8632	WT/DBT IA	1,97,925	76,272	2,43,197	-	-	-	31,000	-	31,000	-
100	"Establishing the causal relationship between genetic disease risk variant of gene SPEN and its underlying molecular neuropathological role in bipolar disorder	8633	WT/DBT IA	16,25,155	33,99,973	-	-	84,789	0	29,85,885	-	29,85,885	19,54,454
101	Genomic Surveillance for SARS-Cov-2 in India: Indian SARS-Cov-2 Genomics Consortium (INSACOG) - Phase II	8635	DBT	19,91,373	1,25,000	-	79,918	79,918	0	9,55,280	-	9,55,280	3,92,578
102	"Organization principles governing the assembly and function of contractile units across scales"	8638	WT/DBT IA	74,95,309	1,30,19,019	-	5,01,929	1,49,654	-	93,89,687	-	93,89,687	1,14,76,916
103	Forcespan nanofiber yarns incorporated with stemcell strips as cardiac path for Myocardial Infarction - Dr. Arthi N	8640	DBT ZBSA	-4,14,404	17,26,832	1,22,152	-	-	9,98,516	11,32,172	-	21,30,688	-9,40,412
104	Elucidating the functional role of RBP4 in regulating neocortical development and its neuropathological role in autism spectrum disorder - Dr. Sreela Kumari Dhanva	8641	DBT ZBSA	-13,21,641	47,21,641	-	-	-	-	15,68,694	-	15,68,694	-4,52,219
105	Insights into the pathogenesis and long-term effects of SARS-Cov-2 variants from structural and immunological perspectives enabling the development of new antiviral modalities	8644	BIRAC	51,13,004	-	-	97,646	-	1,91,997	50,26,958	-	52,18,955	-8,205
106	Elucidating the role of RhoA/BCAS3 in endothelial cell-cardiomyocyte cross-talk and coronary artery disease	8645	SERB	63,223	-	-	1,376	-	-	1,00,000	-	1,00,000	-35,451
107	Development of Novel Cre Reporter Mice Models for Non-Invasive Whole Body Live Imaging for Preclinical Studies	8646	SERB	15,20,727	-	-	-	-	-	6,58,984	-	6,58,984	9,61,743
108	Teachers Association for Excellence to Dr. Akhila Gupta	8637	SERB	28,019	-	-	780	-	-	-	-	-	28,799



Sl No.	Project Title (Name of PI if applicable)	Budget code	Funding Agency	Opening Balance	Received during the year	Refund during the year	Interest received	Interest Refunded	Expenditure	Adjustment	Total Expenditure	Balance as on 31.03.2025
109	Repurposing anti-diabetic drug and related rescue mechanisms for glycogen storage cardiomyopathy	8647	ICMR	21,02,367	-	-	46,887	-	14,08,270	-	14,08,270	7,40,984
110	Role of post-translational modifications of non-tubulin substrates in regulating mammalian cell function	8648	SERB	12,97,957	-	-	-	-	13,89,428	-	13,89,428	-91,471
111	Metabolic exchange and resource sharing strategies in self-organized cellular communities	8649	DBT ZBSA	-	7,00,000	7,00,000	-	-	2,48,000	-	2,48,000	-2,48,000
112	Creation of a national network of existing and upcoming high risk pathogens laboratories (BSL-3/4) labs across departments and keeping their "interlinkages" functional for use during outbreak response across sectors" under NOHM component of PM-ABHIM	8650	ICMR	51,01,654	-	-	71,553	-	11,24,877	-	11,24,877	40,48,330
113	ESCORT: Platform Enabling Stem Cell and Organoid Research and Training	8653	DBT ZBSA	-	1,17,22,625	53,67,625	-	-	62,05,413	-	62,05,413	1,49,587
114	Role of Abi Interactor 1 (ABI1) in cardiac genetics, development and disease	8655	CEFPRA	-	16,86,280	-	22,724	-	9,08,429	-	9,08,429	8,00,575
115	Metabolic Tree-Offs and regulatory Changes as drivers of Metabolic Cross Feeding Interactions in Simple microbial communities	8656	DBT ZBSA	-	14,97,158	5,26,190	-	-	10,09,163	-	10,09,163	-38,195
116	Modelling and molecular mechanisms using cardiac organoids from patient specific iPSC-cardiomyocyte	8657	ANRF	-	17,70,800	-	17,739	-	14,12,109	-	14,12,109	3,76,430
117	Spatial-temporal dynamics of microtubule glutamylation modifications	8658	ANRF	-	21,61,300	-	33,032	-	8,72,971	-	8,72,971	13,21,361
118	Orchestrating microtubule swarming using self propelled nanobots	8660	DBT ZBSA	-	5,40,000	-	-	-	5,40,000	-	5,40,000	-
Total : (A)				5,25,91,821	15,06,97,083	6,25,09,054	16,02,995	8,77,054	2,60,51,060	9,79,44,569	12,39,95,629	1,75,10,163
From other than Government												
119	Research Project awarded by L'oreal (8232- Dr. Colin Jamora)	8232	L'OREAL	5,10,918	-	-	7,904	-	2,57,358	-	2,57,358	2,61,464
120	Agreement with Unilever (8245- Dr. Colin Jamora)	8245	Unilever Industries	4,62,294	-	-	1,828	-	97,130	-	97,130	3,66,992
121	Scientists without boundaries at the Bangalore life science cluster (8283)	8283	TTK	277	-	-	4,12,230	-	4,12,507	-	4,12,507	-0
122	Bugwork Ltd 8457 Ramaswamy	8457	BUGWORK	80,474	-	-	-	-	-	-	-	80,474
123	Support world class research in Neurobiology (8467 Prof. Apurva Sarin)	8467	Prathika Trust	1,43,02,357	-	-	-	-	1,43,02,357	-	1,43,02,357	-
124	Donation from Kiran Mazumdar Shah (8474-Prof. Apurva Sarin)	8474	Kiran Mazumdar Shah	2,21,31,544	-	-	24,53,882	-	67,732	-	67,732	2,45,17,694
125	Joint Agreement between Instem and Eystem (8482-Dr. Arjun Guha)	8482	Eystem-Camp	2,26,809	-	-	-	-	89,688	-	89,688	1,37,121
126	Results of EMBO Young Investigator Programme Selections- 2016 (8275-Minhaluddin Sirajuddin)	8275	EMBO	19,12,360	1,25,175	-	59,418	-	73,329	-	73,329	20,23,624
127	Simons Autism Research Project (8282-Sumnatra Chatterji)	8282	EDINBURGH	78,484	-	-	-	-	-	-	-	78,484
128	Develop an insect (Moscito) repellent formulation based on the natural insecticide nootkatone- 8288 Praveen Vemula	8288	MANUS	3,97,817	-	-	12,912	-	-	-	-	4,10,729
129	Tata Education & Development Trust (8292)	8292	TIGS	1,38,30,419	3,94,92,194	-	65,386	-	2,35,16,883	-	2,35,16,883	1,06,31,823
130	Directors Discretionary Fund (8296)	8296	FLEXI	64,17,405	-	-	-	-	33,22,290	-	33,22,290	31,60,500
131	Terumo Inc (8466) Mahendra Rao	8466	Terumo	23,71,119	-	-	1,69,744	-	-	-	-	23,71,119
132	Collaborative Agreement between Artus & Instem (8472-Dr. Praveen Kumar Vemula)	8472	Artus/ Funded	57,02,927	1,13,576	-	-	-	24,991	-	24,991	49,19,969
133	CSIR & Project Cost Contingency			5,72,013	-	-	-	-	-	-	-	5,72,013
134	Investigation of the Susceptibility UPK3A+Mouse Airways Cells to AUA011/AUA012 (8499)	8499	Genentech	26,354	-	-	26,567	-	4,46,157	-	4,46,157	9,42,479
135	EMBO Global Investigator Network (8501)	8501	CNC Velore/ NCBS/CCAMP	7,59,971	6,02,098	-	1,69,365	-	9,01,825	-	9,01,825	54,72,965
136	Covid RT-PCR for Saliva Samples	8602	Mitosciences Research PVT LTD	62,05,425	-	-	18,612	-	-	-	-	4,79,556
137	Establish assay and research capabilities (As per agreement)	8604	C-CAMP	5,72,936	-	-	-	-	-	-	-	-
138	Anti SARS Activity Service Pipeline	8612	NUS	-13,724	13,724	-	-	-	-	-	-	-
139	NUS	8621	Eystem-Camp	-14,10,885	55,18,335	-	16,352	-	1,88,800	-	1,88,800	36,68,319
140	Eystem-Camp	8630-ES		-89,688	89,688	-	-	-	-	-	-	4,55,483
141												-

SI No.	Project Title (Name of PI if applicable)	Budget code	Funding Agency	Opening Balance	Received during the year	Refund during the year	Interest received	Interest Refunded	Expenditure	Advance	Adjustment	Total Expenditure	Balance as on 31-03-2025
142	GATC	8630- GATC	GATC	-23,709	-	-	-	-	-	-	-	-	-23,709
143	GSBTM	8630- GSBTM	GSBTM	-6,004	-	-	6,004	-	-	-	-	-	-
144	GSBTM-Bridge - SIP	8630- GSBTM - Bridge - SIP	GSBTM - Bridge - SIP	-	2,40,000	-	-	-	68,320	-	-	68,320	1,71,680
145	SUBWARD AGREEMENT NO. 5123689 BETWEEN THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL AND Institute for Stem Cell Science and Regenerative Medicine	8634	SVCF- Chan Zuckenberg Initiative (CZI)	-10,11,629	69,89,682	-	87,453	-	66,91,259	-	-	66,91,259	-6,25,753
146	Exploring the evolution and physiology of the olfactory-immune system connection	8639	Human Frontier Science Program	50,44,387	1,03,34,711	-	2,10,062	-	1,06,57,164	-	-	1,06,57,164	49,31,996
147	Enabling generalizable, stem cell-based Target Assessment Packages (BMGF)	8642	BMGF	11,38,34,758	8,09,75,006	-	1,09,05,492	-	1,83,89,999	-	-	1,83,89,999	11,63,59,238
148	Agreement between inStem and IMCB	8643	IMCB	24,96,446	25,38,620	-	96,354	-	21,43,877	-	-	21,43,877	29,87,543
149	Clinical Evaluation of Hollow Microneedle Device for Painless Intradermal Vaccination	8652	MAHE	9,58,608	9,58,608	-	40,771	-	2,65,595	-	-	2,65,595	16,92,392
150	Machine Learning Approaches in Exploring the Biology of Mental Disorders	8651	IBRO	-	46,88,123	-	-	-	5,83,220	-	-	43,48,463	3,39,660
151	Novel Graft-implanted Macrophage-Targeted Nanomaterials for In Situ Immunosuppression in Vascularized /composite Allotransplantation	8654	DOD MENDS	-	2,30,65,002	-	4,41,973	-	1,07,13,075	-	-	1,07,13,075	1,27,93,900
152	Grant form Dr Reddy's Lab	8659	Dr. Reddy Lab	-	4,00,000	-	2,633	-	1,78,520	-	-	1,78,520	2,24,113
153	Constructing cellular models of Schizophrenia from patients from a clinically dense family	8661	NCBS	-	11,75,000	-	-	-	-	-	-	-	11,75,000
	Sub Total : (C)			19,63,40,463	17,73,19,542	-	1,52,04,941	-	4,27,03,893	-	-	19,19,30,044	19,69,34,903
	Grand Total: (A+B+C+D)			24,89,32,284	32,80,16,625	6,25,09,054	1,68,07,937	8,77,054	6,87,54,953	-	-	31,59,25,972	21,44,43,066

Note: For all negative grants UC and SoE has been submitted to the respective grants for early release of funds.



INSTITUTE FOR STEM CELL SCIENCE AND REGENERATIVE MEDICINE BANGALORE
(Registered under the Karnataka Societies' Registration Act.)
GKVK, BELLARY ROAD, BANGALORE - 560 065
SCHEDULES FORMING PART OF FINANCIAL STATEMENTS AS AT MARCH 31, 2025

(Amount- Rs.)

SCHEDULE -4 - SECURED LOANS AND BORROWINGS:	CY 2024-25	PY 2023-24
1. Central Government	-	-
2. State Government (Specify)	-	-
3. Financial Institutions	-	-
(a) Term Loans	-	-
(b) Interest accrued and due	-	-
4. Banks	-	-
(a) Term Loans	-	-
- Interest accrued and due	-	-
(b) Other Loans (Specify	-	-
- Interest accrued and due	-	-
5. Other Institutions and Agencies	-	-
6. Debentures and Bonds	-	-
7. Others (Specify)	-	-
TOTAL	-	-

(Amount- Rs.)

SCHEDULE -5 - UNSECURED LOANS AND BORROWINGS:	CY 2024-25	PY 2023-24
1. Central Government	-	-
2. State Government (Specify)	-	-
3. Financial Institutions	-	-
(a) Term Loans	-	-
(b) Interest accrued and due	-	-
4. Banks	-	-
(a) Term Loans	-	-
- Interest accrued and due	-	-
(b) Other Loans (Specify	-	-
- Interest accrued and due	-	-
5. Other Institutions and Agencies	-	-
6. Debentures and Bonds	-	-
TOTAL	-	-
Note: Amounts due within one year		

(Amount- Rs.)

SCHEDULE-6 - DEFERRED CREDIT LIABILITIES	CY 2024-25	PY 2023-24
a) Acceptances secured by hypothecation of capital equipment and other assets.	-	-
b) Others	-	-
TOTAL	-	-
Note: Amounts due within one year		



INSTITUTE FOR STEM CELL SCIENCE AND REGENERATIVE MEDICINE BANGALORE
 (Registered under the Karnataka Societies' Registration Act.)
 GKVK, BELLARY ROAD, BANGALORE - 560 065
SCHEDULES FORMING PART OF FINANCIAL STATEMENTS AS AT MARCH 31, 2025

(Amount- Rs.)

SCHEDULE -7 CURRENT LIABILITIES AND PROVISIONS	CY 2024-25	PY 2023-24
A. CURRENT LIABILITIES	-	-
1. Acceptances	-	-
2. Sundry Creditors	1,62,59,726	1,12,48,614
(a) For Goods	1,12,97,555	2,06,06,664
(b) Others	-	-
3. Advance Received	-	-
4. Interest accrued but not due on:	-	-
(a) Secured Loans/Borrowings	-	-
(b) Unsecured Loans /borrowings	-	-
5. Statutory Liabilities :	-	-
(a) Overdue	25,47,101	28,87,316
(b) Others	69,30,792	1,23,63,788
6. Other Current Liabilities	-	-
TOTAL (A)	3,70,35,174	4,71,06,382
B. PROVISIONS	-	-
1. For Taxation	-	-
2. Gratuity	1,14,333	27,68,750.00
3. Superannuation/Pension	-	-
4. Accumulated Leave Encashment	-	19,19,338.00
5. Trade Warranties/Claims	-	-
6. Others	48,81,983	13,45,425
TOTAL (B)	49,96,316	60,33,513
Grand TOTAL (A+B)	4,20,31,491	5,31,39,895



INSTITUTE FOR STEM CELL SCIENCE AND REGENERATIVE MEDICINE, BANGALORE
(Registered under the Karnataka Societies' Registration Act)
GKVK, BELLARY ROAD, BANGALORE - 560 065

SCHEDULE FORMING PART OF BALANCE SHEET FOR THE PERIOD ENDED MARCH 31, 2025

SCHEDULE - 8												
DESCRIPTION	GROSS BLOCK					Rate	DEPRECIATION			NET BLOCK		
	As on 1-4-2024	Additions	Deductions	Up to 31-03-2025			As on 1-4-2024	Additions	Deductions	Upto 31-03-2025	As on 31-03-2025	As on 31-03-2024
(A) Own Funds												
Land Development Works	17,01,110	-	-	17,01,110	0%	7,97,071	-	-	7,97,071	9,04,039	9,04,039	9,04,039
Land (Nominal Value)	1	-	-	1	0%	-	-	-	-	1	1	1
Other Misc. facilities	25,26,642	-	-	25,26,642	10%	16,45,657	88,099	-	17,33,756	7,92,886	8,80,985	8,80,985
Buildings (Residential)*	19,30,49,174	-	-	19,30,49,174	5%	7,69,92,245	58,02,846	-	8,27,95,091	11,02,54,083	11,60,56,929	11,60,56,929
Buildings(Non-Residential)	12,62,57,551	-	-	12,62,57,551	10%	7,80,65,238	48,19,231	-	8,28,84,469	4,33,73,082	4,81,92,313	4,81,92,313
Buildings(Non-Residential)- WIP	62,88,767	-	-	62,88,767	0%	-	-	-	-	62,88,767	62,88,767	62,88,767
Laboratory Equipment	75,75,39,770	10,80,62,620	-	86,56,02,390	15%	44,34,37,820	4,93,13,597	-	49,27,51,417	37,28,50,973	31,41,01,950	31,41,01,950
Laboratory Equipment(WIP)	1,23,22,223	-	-	1,23,22,223	0%	-	-	-	-	1,23,22,223	1,23,22,223	1,23,22,223
Computer Equipment	2,24,79,437	18,32,124	-	2,43,11,561	40%	1,30,59,209	41,66,453	-	1,72,25,661	70,85,900	94,20,228	94,20,228
Office Equipment	1,76,34,065	1,25,94,515	-	3,02,28,580	15%	58,44,201	26,25,618	-	84,69,819	2,17,58,761	1,17,89,864	1,17,89,864
Furniture & Fixture	2,29,48,299	65,58,289	-	2,95,06,588	10%	98,12,641	17,21,532	-	1,15,34,173	1,79,72,415	1,31,35,658	1,31,35,658
Capital / Building	2,04,75,25,028	-	-	2,04,75,25,028	10%	95,11,00,683	10,96,42,435	-	1,06,07,43,118	98,67,81,910	1,09,64,24,345	1,09,64,24,345
Sub Total (A)	3,21,02,72,067	12,90,47,548	-	3,33,93,19,615		1,58,07,54,765	17,81,79,811	-	1,75,89,34,576	1,58,03,85,039	1,62,95,17,302	1,62,95,17,302
(B) Project Funds												
Furniture & Fixture	3,15,984	-	-	3,15,984	10%	2,37,026	7,896	-	2,44,922	71,062	78,958	78,958
Office Equipment - WIP	71,28,496	-	-	71,28,496	0%	-	-	-	-	71,28,496	71,28,496	71,28,496
Laboratory Equipment	1,07,29,89,958	2,68,39,950	-	1,09,98,29,908	15%	72,20,82,650	5,44,25,194	-	77,65,07,843	32,33,22,065	35,09,07,308	35,09,07,308
Laboratory Equipment - WIP	1,16,12,263	1,65,59,416	-	2,81,71,679	0%	-	-	-	-	2,81,71,679	1,16,12,263	1,16,12,263
Buildings(Non-Residential)- WIP	54,88,799	2,53,55,586	-	3,08,44,385	0%	-	-	-	-	3,08,44,385	54,88,799	54,88,799
Buildings(Non-Residential)	18,97,91,403	-	-	18,97,91,403	10%	7,76,10,373	1,12,18,103	-	8,88,28,476	10,09,62,927	11,21,81,030	11,21,81,030
Sub Total (B)	1,28,73,26,903	6,87,54,952	-	1,35,60,81,855		79,99,30,049	6,56,51,193	-	86,55,81,242	49,05,00,613	48,73,96,854	48,73,96,854
(C) CSCR -Vellore												
Buildings	2,46,00,000	-	-	2,46,00,000	10%	79,59,240	16,64,076	-	96,23,316	1,49,76,684	1,66,40,760	1,66,40,760
Laboratory Equipment	36,57,68,180	2,56,01,277	-	39,13,69,457	15%	22,77,33,324	2,36,78,943	-	25,14,12,267	13,99,57,190	13,80,34,856	13,80,34,856
Computer Equipment	3,71,32,641	3,39,604	-	3,74,72,245	40%	3,60,69,361	4,93,233	-	3,65,62,594	9,09,651	10,63,280	10,63,280
Furniture & Fixture	7,875	1,19,652	-	1,27,527	10%	5,528	6,218	-	11,746	1,15,781	2,347	2,347
Sub Total (C)	42,75,08,696	2,60,60,533	-	45,35,69,229		27,17,67,453	2,58,42,470	-	29,76,09,923	15,59,59,306	15,57,41,243	15,57,41,243
(D) Wadhvani Foundation												
Laboratory Equipment	6,84,372	-	-	6,84,372	15%	5,14,196	25,526	-	5,39,722	1,44,650	1,70,176	1,70,176
Computer Equipment	8,48,633	-	-	8,48,633	40%	8,48,352	112	-	8,48,464	169	281	281
Sub Total (D)	15,33,005	-	-	15,33,005		13,62,548	25,638	-	13,88,186	1,44,819	1,70,457	1,70,457
Grand Total (A+B+C+D)	4,92,66,40,671	22,38,63,033	-	5,15,05,03,704		2,65,38,14,815	26,96,99,112	-	2,92,35,13,926	2,22,69,89,778	2,27,28,25,857	2,27,28,25,857

Note 1 : Total additions made to the Fixed Assets during the year amounting to Rs.22,38,63,033 consists of Rs.12,90,47,548/- (FY 23-24 Rs.11,26,79,700/-) acquired out of Core Funds and Rs.6,87,54,952/- (FY 23-24 Rs.3,43,81,832/-) acquired out of Project Funds.

Note 2 : Total Depreciation on Fixed Assets for the year amounts to Rs.26,96,99,112/-, consisting of Rs.17,81,79,811/- (FY 23-24 Rs.21,38,61,721/-) on Fixed Assets acquired out of Core Funds & Rs.6,56,51,193/- (FY 23-24 Rs.7,34,81,963/-) on Fixed Assets acquired out of Project Funds.

*The residential building (50 Nos. Flats) at CB Site Yelahanka is constructed jointly by NCBS and inStem and the land on which it is constructed belong to NCBS. The cost is shared between both the Institutes and there is an MoU signed between both the Institutes to this effect.



INSTITUTE FOR STEM CELL SCIENCE AND REGENERATIVE MEDICINE BANGALORE
 (Registered under the Karnataka Societies' Registration Act.)
 GKVK, BELLARY ROAD, BANGALORE - 560 065
SCHEDULES FORMING PART OF FINANCIAL STATEMENTS AS AT MARCH 31, 2025

(Amount- Rs.)

SCHEDULE -9 - INVESTMENTS FROM EARMARKED /ENDOWMENT FUNDS	CY 2024-25	PY 2023-24
1. In Government Securities	-	-
2. Other approved securities	-	-
3. Shares	-	-
4. Debentures and Bonds	-	-
5. Subsidiaries and Joint Ventures	-	-
6. Others (to be specified)	-	-
TOTAL	-	-

(Amount- Rs.)

SCHEDULE -10 - INVESTMENT OTHERS	CY 2024-25	PY 2023-24
1. In Government Securities	-	-
2. Other approved securities	-	-
3. Shares	-	-
4. Debentures and Bonds	-	-
5. Subsidiaries and Joint Ventures - Shares of C-CAMP- (Company registered under Section 8 Company Act)	600	600
6. Others (to be specified)	-	-
TOTAL	600	600



INSTITUTE FOR STEM CELL SCIENCE AND REGENERATIVE MEDICINE BANGALORE
(Registered under the Karnataka Societies' Registration Act.)
GKVK, BELLARY ROAD, BANGALORE - 560 065
SCHEDULES FORMING PART OF FINANCIAL STATEMENTS AS AT MARCH 31, 2025

(Amount- Rs.)

SCHEDULE -11 - CURRENT ASSETS, LOANS, ADVANCES ETC.	CY 2024-25	PY 2023-24
A. CURRENT ASSETS:		
1. Inventories:		
a) Stores and Spares	61,30,972.04	-
b) Loose Tools	-	-
c) Stock-in-trade	-	-
Finished Goods	-	-
Work -in-progress	-	-
Raw Materials	-	-
2. Sundry Debtors:		
a) Debts outstanding for above six months	23,55,381	19,60,712
b) Others	44,48,789	46,17,840
3. Cash balances in hand (including cheques/drafts)	0	-
4. Bank Balances:		
a) With Scheduled Banks:		
- On current Accounts	1,78,89,192	3,61,49,246
- On Deposits Accounts(includes margin money	28,29,71,001	20,28,71,004
- On Savings Accounts	1,23,15,548	7,14,80,461
b) With Non-Scheduled Banks:		
- On current Accounts	-	-
- On Deposits Accounts(includes margin money	-	-
- On Savings Accounts	-	-
5. Post Office Savings Accounts	-	-
TOTAL (A)	32,61,10,883	31,70,79,263
B. LOANS, ADVANCES AND OTHER ASSETS		
1. Loans:		
a) Staff	-	-
b) Other Entities engaged in activities / Objectives similar to that of the Entity	-	-
c) Others (specify)	-	-
2. Advances and other amounts recoverable in cash or in kind or for value to be received:		
a) On Capital Account	2,04,62,752	1,31,63,358
b) Prepayments	-	-
c) Others	3,16,57,519	3,39,04,107
3. Income Accrued:		
a) On investments from earmarked/endow. Funds	-	-
b) On investments * others	20,46,492	38,51,972
c) On Loans & Advances	-	-
d) Others	-	-
4. Claims Receivable:	46,76,320	1,53,01,986
TOTAL (B)	5,88,43,083	6,62,21,423
GRAND TOTAL (A+B)	38,49,53,966	38,33,00,685



INSTITUTE FOR STEM CELL SCIENCE AND REGENERATIVE MEDICINE BANGALORE
(Registered under the Karnataka Societies' Registration Act.)
GKVK, BELLARY ROAD, BANGALORE - 560 065
SCHEDULES FORMING PART OF FINANCIAL STATEMENTS AS AT MARCH 31, 2025

(Amount- Rs.)

SCHEDULE -12 : INCOME FROM SALES AND SERVICES	CY 2024-25	PY 2023-24
1) Income from Sales	-	-
a) Sale of Finished Goods	-	-
b) Sale of Raw Material	-	-
c) Sale of Scraps	-	-
2) Income from Services:	-	-
a) Labour and Processing Charges	-	-
b) Professional /Consultancy Services	-	-
c) Agency Commission and Brokerage	-	-
d) Maintenance Services (Equipment/ Property)	-	-
e) Others (Facility User charges)	2,15,84,776	2,60,52,807
TOTAL	2,15,84,776	2,60,52,807

(Amount- Rs.)

SCHEDULE -13: GRANTS/SUBSIDIES (Irrevocable Grants and Subsidies received)	CY 2024-25	PY 2023-24
1) Central Government	52,00,00,000	51,23,00,000
2) State Government(s)	-	-
3) Government Agencies	-	-
4) Institutions/Welfare Bodies	-	-
5) International Organizations	-	-
6) Others (specify)-PNB	-	-
TOTAL	52,00,00,000	51,23,00,000

(Amount- Rs.)

SCHEDULE-14: FEES/SUBSCRIPTIONS	CY 2024-25	PY 2023-24
1. Entrance Fees	-	-
2. Annual Fees/Subscriptions	-	-
3. Seminar/Programme Fees	-	-
4. Consultancy Fees	-	-
5. Others (Specify)	-	-
TOTAL	-	-



INSTITUTE FOR STEM CELL SCIENCE AND REGENERATIVE MEDICINE BANGALORE
(Registered under the Karnataka Societies' Registration Act.)
GKVK, BELLARY ROAD, BANGALORE - 560 065
SCHEDULES FORMING PART OF FINANCIAL STATEMENTS AS AT MARCH 31, 2025

(Amount- Rs.)

	CY 2024-25	PY 2023-24
SCHEDULE-15: INCOME FROM INVESTMENTS		
A. Investment from Earmarked Fund		
1) Interest	-	-
a) On Govt. Securities	-	-
b) Other Bonds/Debentures	-	-
2) Dividends	-	-
a) On Shares	-	-
b) On Mutual Fund Securities	-	-
3) Rents	-	-
4) Others (Specify)	-	-
TOTAL (A)	-	-
B. Investment -Others		
1) Interest	-	-
a) On Govt. Securities	-	-
b) Other Bonds/Debentures	-	-
2) Dividends	-	-
a) On Shares	-	-
b) On Mutual Fund Securities	-	-
3) Rents	-	-
4) Others (Specify)	-	-
TOTAL (B)	-	-
Total of income from investment (A+B)	-	-

(Amount- Rs.)

	CY 2024-25	PY 2023-24
SCHEDULE - 16: INCOME FROM ROYALTY, PUBLICATIONS ETC.		
1) Income from Royalty	-	-
2) Income from Publications	-	-
3) Others (Specify)	-	-
TOTAL	-	-



INSTITUTE FOR STEM CELL SCIENCE AND REGENERATIVE MEDICINE BANGALORE
(Registered under the Karnataka Societies' Registration Act.)
GKVK, BELLARY ROAD, BANGALORE - 560 065
SCHEDULES FORMING PART OF FINANCIAL STATEMENTS AS AT MARCH 31, 2025

(Amount- Rs.)

SCHEDULE - 17 : INTEREST EARNED	CY 2024-25	PY 2023-24
1) On Term Deposits:		
a) With Scheduled Banks	30,94,634	15,07,925
b) With Non-Scheduled Banks	-	-
c) Interest of CSCR Vellore	-	-
d) Others	-	-
2) On Savings Accounts:		
a) With Scheduled Banks	3,34,790	6,31,000
b) With Non-Scheduled Banks	-	-
c) With Institutions	-	-
d) Others	-	-
3) On Loans:		
a) Employees /Staff	-	-
b) Others	-	-
4) Interest on Debtors and Other Deposits	6,59,005	2,46,717
TOTAL	40,88,429	23,85,642

(Amount- Rs.)

SCHEDULE - 18: OTHER INCOME	CY 2024-25	PY 2023-24
1) Profit on Sale /disposal of Assets:		
a) Owned assets	-	-
b) Assets acquired out of grants, or received free of cost	-	-
2) Export Incentives realized		
3) Recovery - EMG Overheads	1,30,34,465	53,00,937
4) Fees for Miscellaneous Services	6,51,995	5,85,934
5) Miscellaneous Income *	49,46,291	21,46,766
6) Net Gain/Loss from foreign currency Transaction	-	8,488
TOTAL	1,86,32,752	80,42,125

(Amount- Rs.)

SCHEDULE - 19: INCREASE/DECREASE IN STOCK OF FINISHED GOODS & W.I.P	CY 2024-25	PY 2023-24
a) Closing stock		
- Finished Goods	-	-
- Work-in-progress	-	-
TOTAL (A)	-	-
b) Less: Opening Stock - Finished Goods		
- Work-in-progress	-	-
Total (B)	-	-
NET INCREASE/(DECREASE) (A+B)	-	-



INSTITUTE FOR STEM CELL SCIENCE AND REGENERATIVE MEDICINE BANGALORE
(Registered under the Karnataka Societies' Registration Act.)
GKVK, BELLARY ROAD, BANGALORE - 560 065
SCHEDULES FORMING PART OF FINANCIAL STATEMENTS AS AT MARCH 31, 2025

(Amount- Rs.)

SCHEDULE - 20: ESTABLISHMENT EXPENSES	CY 2024-25	PY 2023-24
a) Salaries and Wages	10,94,56,263	10,74,62,027
b) Prior Period Salaries	-	-
c) Contribution to Provident Fund-NPS*	1,14,12,788	1,13,02,516
d) Contribution to other Fund (specify) - LS & Pension Contributions	2,09,33,481	51,27,519
e) Staff Welfare /expenses	4,23,392	1,99,783
f) Expenses on Employees' Retirement and Terminal Benefits	-	-
g) Others (specify)	-	-
h) Fellowships (JRF/SRF)	-	-
TOTAL	14,22,25,924	12,40,91,845

(Amount - Rs.)

SCHEDULE - 21: OTHER ADMINISTRATIVE EXPENSES ETC.	CY 2024-25	PY 2023-24
a) Purchases - Laboratory & Computer Consumables	10,94,52,479	10,26,29,094
b) other Laboratory expenses	3,35,90,660	42,05,290
c) Membership Fees	2,89,634	14,01,400
d) Electricity and power	4,84,73,045	5,50,89,880
e) Water charges	25,44,946	30,21,090
f) Contract for Services	6,11,94,228	5,12,07,503
g) Repairs & Maintenance	4,67,68,558	6,02,28,313
h) Training	1,74,520	-
i) Rent, Rates, Taxes and fees	59,44,065	19,03,183
j) Vehicles running and maintenance	6,48,000	6,48,000
k) Potage, Telephone and Communication charges	13,73,136	13,81,203
l) Printing and Stationery	7,60,112	13,84,751
m) Travelling & Conveyance Expenses	60,55,078	58,00,606
n) Expenses on Seminars/Workshops	5,01,496	23,59,278
o) Subscription Expenses	14,49,464	5,68,465
p) Expenses on Fees - Consultancy Fee/Honorarium	16,70,385	17,07,758
q) Auditors Remuneration	1,45,300	1,46,200
r) Hospitality Expenses	5,70,882	8,17,039
s) Security Charges	1,50,18,980	1,70,77,689
t) Bank Charges	26,603	41,979
u) Other Contingent Expenditure	16,48,835	34,69,316
v) Advertisement & Publicity	20,96,375	10,69,193
w) Campus maintenance	1,45,08,884	1,52,33,267
x) Canteen Expenses	80,17,579	92,84,538
y) Professional fees	7,86,325	8,301
z) Other office Expenses	67,53,089	91,96,804
TOTAL	37,04,62,659	34,98,80,140

Note: From FY 2024-25 onwards, the fellowship paid to students and outsourced staff is accounted under the 'Contract for Services' head. Accordingly, the previous year's figures have been restated.



INSTITUTE FOR STEM CELL SCIENCE AND REGENERATIVE MEDICINE BANGALORE
(Registered under the Karnataka Societies' Registration Act.)

GKVK, BELLARY ROAD, BANGALORE - 560 065

SCHEDULES FORMING PART OF INCOME & EXPENDITURE ACCOUNT FOR THE YEAR ENDED MARCH 31, 2025

(Amount - Rs.)

SCHEDULE - 22: EXPENDITURE ON GRANTS, SUBSIDIES ETC.	CY 2024-25	PY 2023-24
a) Grants given to Institutions/Organizations	-	-
b) Subsidies given to Institutions/Organizations	-	-
c) Expenditure incurred on Grants (As per Schedule -3)	24,71,70,719	17,27,23,704
TOTAL	24,71,70,719	17,27,23,704

(Amount - Rs.)

SCHEDULE - 23: INTEREST	CY 2024-25	PY 2023-24
a) On fixed loans	-	-
b) On other Loans (including Bank Charges)	-	-
c) Others (specify)	36,75,683	5,81,934
TOTAL	36,75,683	5,81,934



**INSTITUTE FOR STEM CELL SCIENCE AND REGENERATIVE MEDICINE,
BANGALORE**

(Registered under the Karnataka Societies' Registration Act)
GKVK, BELLARY ROAD, BANGALORE - 560 065

**SCHEDULE FORMING PART OF ANNUAL ACCOUNTS FOR THE PERIOD
ENDED MARCH, 31, 2025**

SCHEDULE 25 - CONTINGENT LIABILITIES AND NOTES ON ACCOUNTS

1. CONTINGENT LIABILITIES

1.1 In respect of:

- Bank guarantees given by / on behalf of the Entity - Rs. NIL /- (Previous year Rs. NIL/-)
- Letters of Credit opened by Bank on behalf of the Entity - Rs. NIL/- (Previous year Rs. NIL/-)
- Bills discounted with banks Rs. NIL/- (Previous year Rs. NIL/-)

1.2 Disputed demands in respect of:

- Income-tax Rs. NIL/- (Previous year Rs. NIL/-)
- Sales-tax Rs. NIL/- (Previous year Rs. NIL/-)
- Municipal Taxes Rs. NIL/- (Previous year Rs. NIL/-)

1.3 In respect of claims from parties for non-execution of orders, but contested by the Entity - Rs. NIL/- (Previous year Rs. NIL/-)

1.4 NCBS-TIFR was the Project Managing Agency (PMA) for the construction of inStem Building. Accordingly, NCBS - TIFR (PMA) issued work orders for Construction of Buildings for Laboratories & Associated facilities, one of such work order was issued on M/s. URC Constructions in pre-GST regime.

Against the said Work Order M/s. URC Construction claimed amount towards GST at the rate of 18% which has been disputed by NCBS-TIFR (PMA) on the basis of circular No. SE/TAS/GST/04 from CPWD dated 22.09.2017. M/s. URC had invoked arbitration (A. C. No. 401 / 2022) and the arbitrator issued order dt. 30.08.2024 in favour of M/s.URC with total award value of Rs. 3.53 Crores including interest (Basic Amount Rs.2.0318 Crore + Rs.1.4932 Crore Interest).

Currently, NCBS-TIFR (PMA) has filed an appeal before the High Court of Bengaluru vide Filing No. 368/2025 dated 25th June 2025. The matter is sub judice and yet to be heard.

As on 31.03.2025, an advance amount of Rs.1.52 Crore is with NCBS.



2. CAPITAL COMMITMENTS

Estimated value of contracts remaining to be executed on capital account and not provided for Rs. NIL/-.

3. LEASE OBLIGATIONS

Future obligations for rentals under finance lease agreements for plant and machinery amount to Rs.NIL/- (Previous year Rs. NIL/-).

4. CURRENT ASSETS, LOANS AND ADVANCES

In the opinion of the Management, the current assets, loans and advances have a value on realization in the ordinary course of business, equal at least to the aggregate amount shown in the Balance Sheet.

InStem has started its Stores operations from the FY 2024-25 and accordingly the closing inventory has been accounted.

5. TAXATION

The Society is registered under section 12A of the Income Tax Act, 1961 under the category Charitable Trust. The Society is filing the income tax return by claiming exemption under section 11 of the Income Tax Act, 1961.

6. FOREIGN CURRENCY TRANSACTIONS

(Amount in Rs.)

6.1 Value of Imports Calculated on C.I.F. Basis:

Particulars	Current Year	Previous Year
Purchase of Finished Goods	NIL/-	NIL/-
Raw Material & Components (including in transit)	NIL/-	NIL/-
Capital Goods	0	0
Stores, Spares & Consumables	58,43,177	91,51,218

6.2 Expenditure in foreign currency:

Particulars	Current Year	Previous Year
Travel	7,09,058	29,26,095
Interest payment	NIL/-	NIL/-
Collaboration Expense	NIL/-	NIL/-
Remuneration	NIL/-	1,30,215
Publication charges & Training	31,33,922	27,15,348

6.3 Earnings:

Particulars	Current Year	Previous Year
Value of Exports	Nil	20,46,701



7. Remuneration to auditors

Particulars	Amount(Rs.)
As Statutory Auditors*	130,000/-
For Taxation Matters	85,000/-
For Certification	6,000/-

* Audit fee for inStem and CSCR is Rs.85,000/- (exclusive of GST) and Rs.45,000/- (excluding GST) respectively.

8. The Institute, National Centre for Biological Sciences (NCBS), Tata Institute Genetics and Society and C-Camp are located in a common campus. As per the MOU entered into between the four(4) entities, common expenditure incurred by any institute is shared by other three entities. The Institute accounts these expenditures on the basis of the Debit Note raised by respective institutes.
9. Interest earned during FY 2023-24 amounting to ₹21,38,925/- was remitted to the Consolidated Fund of India vide Bharatkosh Receipt Nos. 0708240032082 dated 07.08.2024 and 1305240019863 dated 13.05.2024, which has been adjusted under Recurring Grant (Ref: Schedule-1). Further, a provision of ₹36,73,841/- towards refund of interest earned during FY 2024-25 has been created in the books of accounts.
10. Expenses are allocated between Core and EMG based on the scientific progress achieved in laboratories utilising common inputs.
11. The Share Certificates of C-CAMP are held in the name of the former Director of the Institute/individuals, in their capacity as a representative of the Institute.
12. The Institute's Building and Infrastructure are located on Lease Hold Land. The lease deed is between The University of Agricultural Sciences (UAS) and Department of Bio-Technology, Ministry of Science and Technology (DBT) have entered into a Lease Deeds on 04-11-2009 whereby the UAS has granted 20 acres of land on 49 years of lease to DBT for establishment of the Institute.
13. Corresponding figures for the previous year have been regrouped / rearranged, wherever necessary.
14. Schedules 1 to 25 are annexed to and from an integral part of the Balance Sheet as at March 31, 2025 and the Income and Expenditure Account for the year ended on that date.



**INSTITUTE FOR STEM CELL SCIENCE AND REGENERATIVE MEDICINE,
BANGALORE**

(Registered under the Karnataka Societies' Registration Act)
GKVK, BELLARY ROAD, BANGALORE - 560 065

**SCHEDULE FORMING PART OF ANNUAL ACCOUNTS FOR THE PERIOD
ENDED MARCH, 31, 2025**

SCHEDULE 24 - SIGNIFICANT ACCOUNTING POLICIES

1. ACCOUNTING CONVENTION

The Financial statements are prepared on the basis of historical cost convention.

2. INVESTMENTS

Investment are carried at cost. The decline in their value, which is other than temporary is provided for.

3. PROPERTY, PLANT & EQUIPMENT (PPE)

3.1 PPE are capitalized at cost of acquisition inclusive of inward freight, duties and taxes and incidental and direct expenses related to acquisition and it is carried in the balance sheet net of accumulated depreciation.

3.2 Cost of PPE acquired out of project funds are also taken as Assets by debiting the appropriate head of Fixed Assets of the Institute and by crediting corresponding amount to Capital Reserve. Every year Capital reserve is reversed to the extent of depreciation, calculated under the WDV method at the rates of depreciation prescribed under the Income Tax Rules, 1962. In the event of the asset being returned to the agency sanctioning the grant, the written down value will be adjusted by reversing the entries.

4. DEPRECIATION

4.1 Depreciation is provided on written down value method as per rates specified in the Income-tax Act, 1961.

4.2 Depreciation of assets commences when the assets are ready for their intended use which is generally on commissioning/installation. The total amount of depreciation on assets acquired out of Core and EMG funds for the year is transferred from Capital Reserve to Income and Expenditure Account.

5. GOVERNMENT GRANTS / SUBSIDIES

5.1 Grants received from the Government are of two types: (a) Non-Recurring Grants - which are for the purpose of acquiring Capital Assets. The amount of grants received is initially credited to Corpus / Capital fund account and expenditure incurred for acquisition of capital assets is debited thereto. The balance in this account represents the unspent amount of non-recurring grant. The amount equivalent to capital assets added during the year is added to capital reserve account. (b) Recurring Grants - which are for the purpose of recurring expenditure and are taken directly to Income & Expenditure Account. Unspent balance/excess of expenditure over income is shown in Reserves & Surplus Account distinctly under General Reserve. The combined balance in this account is the total unspent balance of grants.

5.2 Government grants / subsidy are accounted on receipt basis.



6. EARMARKED/ENDOWMENT FUNDS

- 6.1 Project Funding by both Government and non-government agencies to whom a statement of account of the expenditure incurred together with a utilization Certificate of the amount released has to be furnished are accounted under this heading. Fellowships/Scholarships sanctioned by UGC/CSIR and other agencies are also accounted under this head in order to watch the balance available/recoverable on each such award. Based on the conditions and limits stipulated in the sanction order, expenditure is incurred.
- 6.2 Such Earmarked/Endowment Funds towards specific projects, to the extent unspent is carried in the Balance Sheet as a liability under the head "Earmarked/Endowment Funds". Project-wise details of funds received and corresponding expenditure during the year is furnished along with opening and closing unspent balances of specific funds under Schedule 3. Upon Completion of the project in its entirety, the same is removed from the list in Schedule 3. When tangible Fixed Assets are acquired out of the projects funds, the appropriate head of Fixed Assets is debited with corresponding credit to Capital Reserve. Every year Capital reserve is reversed to the extent of depreciation, calculated under the WDV method at the rates of depreciation prescribed under the Income Tax Rules, 1962.

7. FOREIGN CURRENCY TRANSACTIONS

- 7.1 Transactions denominated in foreign currency are accounted at the exchange rate prevailing at the date of the transaction.
- 7.2 Current assets, foreign currency loans and current liabilities are converted at the exchange rate prevailing as at the year end. The resultant gain / loss is adjusted to cost of fixed assets, if the foreign currency liability relates to fixed assets, and in other cases is considered to revenue.

8. LEASE

Lease rentals are expensed with reference to lease terms.

9. RETIREMENT BENEFITS

- 9.1 The provision for leave encashment is provided based on the actuarial valuation. The Institute has a plan with Life Insurance Corporation of India who provides the actuarial valuation.
- 9.2 The provision for gratuity is provided based on the actuarial valuation. The Institute has a group gratuity plan with Life Insurance Corporation of India who provides the actuarial valuation.

10. REVENUE RECOGNITION

10.1 INCOME FROM FACILITY SERVICES: Income is derived from services in relation to usage of facilities available at the institute by external users and are billed at specified rate on accrual basis along with applicable GST.

10.2 INTEREST FROM BANKS: Interest earned is accounted on accrual basis as per bank statement.

10.3 MISC INCOME: Includes charges for internal usage of facilities at the institute for research purposes is accounted under this head. As this is purely for internal purposes GST is not applicable.

